Skip to main content

Genetic Technologies CEO, Others Resign Following Annual Meeting

NEW YORK (GenomeWeb News) – Paul MacLeman, CEO of Australian firm Genetic Technologies, and other members of the firm's board and executive team resigned Tuesday following the firm's annual general meeting.

The resignations came after Chairman Mel Bridges and Director Huw Jones were not re-elected to the firm's board. Those two will leave the board along with Director Greg Brown, who resigned following the results of the voting even though he was re-elected. David Sparling, VP of legal and corporate development for the firm, also tendered his resignation.

GenomeWeb Daily News was unable to receive additional information and comment from Genetic Technologies by the time this article was published. However, the website of Australia's national newspaper, The Australian, reported that Genetic Technologies Founder Mervyn Jacobson had used his 29 percent stake in the firm to block the re-elections of Bridges and Jones.

"Dr. Bridges said it is regrettable that a company with the potential of GTG was unable to reach middle ground with its major shareholder," Genetic Technologies said in a statement posted on its website.

Genetic Technologies sells the BrevaGen breast cancer risk stratification test. The firm recently reported a 50 percent decline in first-quarter revenues.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.